Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02664012
Other study ID # CSD1501
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date May 2016

Study information

Verified date May 2018
Source R.J. Reynolds Vapor Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to measure plasma nicotine uptake parameters, physiological measures, and subjective effect measures in smokers during and following a single ad libitum use of three menthol electronic cigarettes versus combustible menthol cigarettes and nicotine gum.


Description:

This study will assess various elements that may provide information regarding the potential for menthol electronic cigarettes (e-cigarettes) to be adopted by current smokers. These various elements include: a) nicotine pharmacokinetics (PK), b) physiological measures of pulse rate and blood pressure, and c) subjective effects measured by Urge to Smoke, Urge for Product, Product Rating, Intent to Use Product Again, and Product Effects.


Recruitment information / eligibility

Status Completed
Enrollment 71
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 60 Years
Eligibility Inclusion Criteria:

1. Able to read, understand, and willing to sign an informed consent form and complete questionnaires written in English.

2. Generally healthy male or female, 21 to 60 years of age, inclusive, at Screening.

3. Expired breath carbon monoxide (ECO) level is = 15 ppm and = 100 ppm at the Screening and Randomization Visits, measured between 12 p.m. and 6 p.m.

4. Combustible menthol cigarettes are the only tobacco product used within (=) 30 days of Screening.

5. Smokes combustible, filtered, menthol cigarettes, 83 mm to 100 mm in length.

6. Agrees to smoke usual brand (UB) menthol cigarette throughout the study period. Usual brand cigarette is defined as the menthol cigarette brand style currently smoked most frequently by the subject.

7. Smokes at least 10 menthol cigarettes per day (on average) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Investigator.

8. Response at Screening to Fagerstrom Test for Nicotine Dependence, Question 1 ("How soon after you wake up do you smoke your first cigarette?") is either "Within 5 minutes" or "6 - 30 minutes."

9. Willing to use UB menthol cigarette, the study electronic cigarette menthol brand styles and nicotine gum during the study period.

10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to check-in at each Test Visit.

11. Females of childbearing potential must be willing to use a form of contraception acceptable to the Investigator from the time of signing informed consent until study discharge.

Exclusion Criteria:

1. Clinically significant or unstable/uncontrolled acute or chronic medical conditions at Screening, as determined by the Investigator, that would preclude a subject from participating safely in the study (e.g., uncontrolled hypertension, asthma or other lung disease, cardiac disease, neurological disease or psychiatric disorders) based on safety assessments such as clinical laboratory tests, medical history, and physical/oral examinations.

2. Systolic blood pressure of > 150 mmHg or a diastolic blood pressure of > 95 mmHg at Screening, measured after being seated for at least 5 minutes.

3. Hemoglobin level is < 12 g/dL at Screening.

4. Positive test for Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C virus.

5. Postponing a decision to quit smoking (defined as planning a quit attempt within [=] 30 days of Screening) to participate in this study or previous attempt within (=) 30 days prior to Screening.

6. Employed by a tobacco company, the study site, or handles unprocessed tobacco as part of their job.

7. Use of any medication or supplement that aids smoking cessation, including but not limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch), varenicline (Chantix), bupropion (Wellbutrin, Zyban), or lobelia extract within (=) 30 days of Screening.

8. Females = 35 years of age currently using systemic, estrogen containing contraception or hormone replacement therapy.

9. A positive urine drug screen without disclosure of corresponding prescribed concomitant medication(s), at Screening or Randomization Visit. A positive alcohol result at Screening, Randomization Visit, or at any Test Visit.

10. A female who is pregnant, lactating, or intends to become pregnant during the course of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Own Brand Menthol Cigarette
combustible menthol cigarette brand style smoked most frequently by subject
Electronic Menthol Cigarette #1
VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
Electronic Menthol Cigarette #2
VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
Electronic Menthol Cigarette #3
VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
Leading U.S. Nicotine Gum
4 mg nicotine polacrilex gum

Locations

Country Name City State
United States Celerion Lincoln Nebraska

Sponsors (3)

Lead Sponsor Collaborator
R.J. Reynolds Vapor Company Celerion, RAI Services Company

Country where clinical trial is conducted

United States, 

References & Publications (1)

Stiles MF, Campbell LR, Jin T, Graff DW, Fant RV, Henningfield JE. Assessment of the abuse liability of three menthol Vuse Solo electronic cigarettes relative to combustible cigarettes and nicotine gum. Psychopharmacology (Berl). 2018 May 3. doi: 10.1007/ — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Maximum change in blood pressure relative to baseline Determine the maximum change in blood pressure Baseline and at timed intervals over 360 minutes following initiation of IP use
Other Subjective effects scores for Urge for Product (UFP) with respect to initiation of in-clinic IP use (e-cigarettes and nicotine gum only) following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine area under the UFP score-versus-time curve (AUEC) -10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes
Other Subjective effects scores for UFP with respect to initiation of in-clinic IP use (e-cigarettes and nicotine gum only) following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine maximum UFP score -10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes
Other Subjective effects scores for UFP with respect to initiation of in-clinic IP use (e-cigarettes and nicotine gum only) following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine time to maximum UFP score -10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes
Other Perform CYP2A6 genotyping A) Assess the impact of CYP2A6 genotype on nicotine uptake and subjective effects following a 12-hour tobacco and nicotine abstinence and B) Explore a potential relationship between CYP2A6 genotype and phenotype Once, at time of randomization
Other Perform phenotyping (i.e., nicotine metabolic ratio of cotinine:3-hydroxy cotinine) A) Assess the impact of phenotypic ratio on nicotine uptake and subjective effects following a 12-hour tobacco and nicotine abstinence and B) Explore a potential relationship between CYP2A6 genotype and phenotype Once, at time of randomization
Primary Nicotine pharmacokinetics with respect to initiation of in-clinic investigational product (IP) use following a 12-hour tobacco and nicotine abstinence Determine area under the plasma nicotine concentration versus time curve (AUC) -5, -0.5, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes
Primary Nicotine pharmacokinetics with respect to initiation of in-clinic investigational product (IP) use following a 12-hour tobacco and nicotine abstinence Determine maximum plasma nicotine concentration (Cmax), baseline adjusted -5, -0.5, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes
Primary Nicotine pharmacokinetics with respect to initiation of in-clinic investigational product (IP) use following a 12-hour tobacco and nicotine abstinence Determine time to maximum plasma nicotine concentration (Tmax), baseline-adjusted -5, -0.5, 5, 7.5, 10, 15, 20, 30, 45, 60, 75, 90, 120, 150, 180, 240, 300, 360 minutes
Primary Subjective effects scores for Urge to Smoke (UTS) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a numeric rating scale (NRS) to determine area under the UTS score-versus-time curve [area under the effect curve (AUEC)] -10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes
Primary Subjective effects scores for Intent to Use Again (IUA) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine area under the IUA score-versus-time curve (AUEC) 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Primary Subjective effects scores for Product Ratings (PR) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine area under the PR score-versus-time curve (AUEC) 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Primary Subjective effects scores for Positive Product Effects (PE) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine area under the Positive PE score-versus-time curve (AUEC) 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Primary Subjective effects scores for Negative Product Effects (PE) with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine area under the Negative PE score-versus-time curve (AUEC) 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Primary Maximum change in pulse rate relative to baseline Determine the maximum change in pulse rate Baseline and at timed intervals over 360 minutes following initiation of IP use
Primary Baseline cotinine measured pre-IP use Evaluate changes in baseline cotinine to assess whether subjects substantially changed their nicotine uptake during the study -0.5 minute (baseline) and -5 min (back-up baseline) for each IP
Primary Change in expired carbon monoxide (ECO) relative to baseline Assess change in ECO from baseline following IP use Baseline and 35 minutes post-IP use
Primary Subjective effects scores for UTS with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine minimum UTS score -10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes
Primary Subjective effects scores for UTS with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine time to minimum UTS score -10, 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, 300, 360 minutes
Primary Subjective effects scores for IUA with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine maximum IUA score 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Primary Subjective effects scores for PR with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine maximum PR score 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Primary Subjective effects scores for Positive PE with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine maximum Positive PE score 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
Primary Subjective effects scores for Negative PE with respect to initiation of in-clinic IP use following a 12-hour tobacco and nicotine abstinence Score subjective effects using a NRS to determine maximum Negative PE score 15, 30, 45, 60, 120, 180, 240, 300, 360 minutes
See also
  Status Clinical Trial Phase
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT03931772 - Online Automated Self-Hypnosis Program N/A
Completed NCT02649556 - A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 N/A
Completed NCT03901066 - Smoking Dependence and Periodontitis
Recruiting NCT05846841 - Personalized Tobacco Treatment in Primary Care (MOTIVATE) N/A
Completed NCT03170752 - Implementing and Testing a Cardiovascular Assessment Screening Program (CASP) N/A
Completed NCT03305978 - Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. N/A
Completed NCT00000437 - Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Phase 4
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Active, not recruiting NCT02752022 - Monitoring the Transition From Smoking to E-cigarettes
Completed NCT02912000 - TEACH: Technology Evaluation to Address Child Health N/A
Completed NCT04340830 - The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants N/A
Completed NCT02901171 - The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation N/A
Completed NCT03206619 - A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
Completed NCT02949648 - Electronic Cigarette Use and Quitting in Youth N/A
Completed NCT02246114 - Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women N/A
Completed NCT02945371 - Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life N/A
Completed NCT02008292 - Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors N/A
Completed NCT03448900 - Intervention Study for Smoking Cessation in Spanish College Students N/A
Completed NCT01898507 - Nicotine Metabolism and Low Nicotine Cigarettes N/A